Defeudis Francis V
Institute for BioScience, 153 West Main Street, Westboro, MA 01581, USA.
Pharmacol Res. 2002 Dec;46(6):565-8. doi: 10.1016/s1043-6618(02)00233-5.
In vivo studies have indicated that systemically administered bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba leaf extracts, can reduce cerebral edema produced by triethyltin, decrease cortical infarct volume in certain stroke models, and reduce cerebral ischemia. In vitro and ex vivo studies indicate that bilobalide has multiple mechanisms of action that may be associated with neuroprotection, including its preservation of mitochondrial ATP synthesis, its inhibition of apoptotic damage induced by staurosporine or by serum-free medium, its suppression of hypoxia-induced membrane deterioration in the brain, and its actions of increasing the expression of the mitochondrial DNA-encoded COX III subunit of cytochrome c oxidase and the ND1 subunit of NADH dehydrogenase. As multiple modes of action may apply to bilobalide, it could be useful in developing therapy for disorders involving cerebral ischemia and neurodegeneration.
体内研究表明，银杏叶提取物中的倍半萜三内酯成分白果内酯经全身给药后，可减轻三乙基锡引起的脑水肿，在某些中风模型中减小皮质梗死体积，并减轻脑缺血。体外和离体研究表明，白果内酯具有多种可能与神经保护相关的作用机制，包括其对线粒体ATP合成的维持作用、对星形孢菌素或无血清培养基诱导的凋亡损伤的抑制作用、对脑内缺氧诱导的膜退化的抑制作用，以及增加细胞色素c氧化酶的线粒体DNA编码的COX III亚基和NADH脱氢酶的ND1亚基表达的作用。由于白果内酯可能具有多种作用模式，它可能有助于开发针对涉及脑缺血和神经退行性变疾病的治疗方法。
